Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of CC-486 (oral azacitidine) in MDS after failure of injectable HMAs
2014-002675-29Phase 2Active
- Sponsor
- Celgene Corporation
- Start
- Jul 2015
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-486 in myelodysplastic syndrome (MDS), sponsored by Celgene Corporation. Primary endpoint: Overall rate of objective response. Started Jul 2015; status: active.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2014-002675-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002675-29.